The Memo: Bairitone Health Is Bringing Anatomical Insight Into Sleep Apnea Care

Under the direction of Co-Founder and CEO Meagan Pitcher, PhD, Bairitone Health is developing a noninvasive, at-home diagnostic designed to identify where and how the airway collapses during natural sleep. Rather than replacing conventional sleep testing, the Houston-based company aims to add an anatomical layer that can help clinicians move beyond determining the severity of obstructive sleep apnea and toward selecting the most appropriate treatment for each patient. With FDA Breakthrough Device Designation, a growing clinical research program, and a recently closed oversubscribed $2.4 million Seed round, Bairitone is working to make advanced anatomical diagnostics accessible in routine sleep apnea care.

Origin Story

Bairitone’s origins trace back to 2022, when Pitcher met fellow co-founders Dr. Onur Kilic and Dr. Britt Cross through a Biodesign program at the Texas Medical Center in Houston. As the team explored unmet clinical needs, sleep apnea repeatedly surfaced as a comorbidity, prompting them to investigate the condition more closely.

What caught their attention was not a lack of treatment options, but a disconnect between those treatments and the information available to guide their selection.

“There were a growing number of ways to treat sleep apnea, but relatively little innovation in diagnostics beyond moving sleep studies from the lab into the home,” Pitcher said. “The most accessible diagnostic tools could tell clinicians how severe a patient’s sleep apnea was, but not where the airway was collapsing or which treatment might work best.”

More detailed anatomical assessments existed, but they were invasive and difficult to scale. Kilic’s expertise in acoustic sensing offered the team another possibility: using the vibrations generated during breathing to understand what was happening within the airway.

“We sketched the concept on a whiteboard and built our first prototype within a couple of weeks,” Pitcher recalled. 

That early concept has since developed into a clinical-stage diagnostic platform. Bairitone remains based in Houston and is initially focused on the U.S. market, where the team is building clinical evidence, pursuing FDA authorization, and establishing the partnerships needed to integrate the technology into clinical practice.

The Current Landscape

Obstructive sleep apnea presents a treatment-selection challenge that is becoming increasingly important as the therapeutic landscape expands. Bairitone points to an estimated 23 million Americans with moderate to severe disease and estimates that approximately 700,000 patients each year struggle with adherence to CPAP, the first-line therapy.

For those patients, alternatives increasingly include neurostimulation, dental and oral appliances, and surgical interventions. But more options also make understanding the mechanism behind an individual patient’s airway obstruction increasingly relevant, both for selecting the right treatment and optimizing it over time.

“Today, sleep apnea is largely diagnosed and characterized by how frequently a patient stops breathing, rather than why those obstructions occur,” Pitcher explained. “We believe understanding the underlying anatomy is essential to making better treatment decisions, especially as the number of available therapies continues to grow.”

The standard diagnostic pathway illustrates the gap Bairitone is targeting. Obstructive sleep apnea is typically diagnosed through polysomnography in a sleep laboratory or a home sleep apnea test. These approaches measure disease severity by counting breathing interruptions, but do not identify where the airway is collapsing or indicate which treatment is most likely to succeed.

Patients being considered for advanced therapies may undergo drug-induced sleep endoscopy (DISE), in which the patient is sedated while a flexible camera is used to observe airway collapse. Although DISE can provide valuable anatomical information, it generally requires specialized personnel and facilities and evaluates the airway under sedation rather than during natural sleep.

Bairitone is working to bridge those two ends of the diagnostic spectrum.

“We’re not trying to replace conventional sleep testing,” Pitcher said. “We’re developing the missing anatomical layer that can help clinicians move from diagnosing sleep apnea to selecting the right treatment.”

With approximately 2 million CPAP prescriptions written annually in the U.S., Bairitone sees a significant opportunity to eventually bring that anatomical insight into routine sleep apnea diagnosis, beyond its initial focus on patients considering alternative therapies.

Inside the Innovation

Bairitone’s technology uses a small wearable patch with an array of sensors placed along the face. During natural sleep, the sensors passively capture vibrations traveling through the tissues of the head and neck as the patient breathes.

Proprietary signal processing and machine learning algorithms analyze how those vibrations propagate between sensors. The resulting patterns contain information about the location and configuration of airway obstructions, which Bairitone is using to develop an anatomical map of how the airway collapses during sleep. The company is also developing the ability to identify obstruction at multiple levels of the airway.

“Our goal is to translate these complex signals into a clinically useful anatomical report, giving physicians information they can use to guide treatment decisions across a growing range of therapies without requiring an invasive procedure,” Pitcher said.

The approach is intended to bring anatomical assessment into a patient’s own bed, during natural sleep, without sedation or the specialized facilities required for DISE. Because the technology is noninvasive, Bairitone sees potential for the information to support decisions across multiple therapeutic options, including helping clinicians identify patients who may not be good candidates for particular procedures.

By improving treatment selection, Bairitone also sees the potential to reduce repeated treatment failures and associated healthcare costs, creating value for patients, clinicians, and payors.

Ultimately, the company’s mission extends beyond the diagnostic itself.

“Our mission is to make personalized sleep apnea treatment possible by bringing advanced anatomical diagnostics into routine clinical care,” Pitcher said.

Progress and Milestones

Bairitone has advanced from its initial whiteboard concept to a functioning diagnostic platform now being evaluated in human clinical studies. In 2026, the company received FDA Breakthrough Device Designation and completed enrollment of its first 50 clinical study participants. It has also begun expanding its clinical research program beyond Houston to additional clinical sites.

For Pitcher, that progress is particularly meaningful in light of the capital efficiency with which the company has reached these milestones.

“One of the accomplishments I’m most proud of is how much we’ve achieved with relatively little capital,” she said. “Since [Bairitone’s founding in 2022], we’ve built the technology from the ground up, advanced into human clinical studies, and received FDA Breakthrough Device Designation, with approximately $1 million in net capital deployed.”

Bairitone was also recognized through the American Academy of Sleep Medicine’s Sleep Medicine Disruptors program, where its anatomic polysomnogram was selected as the diagnostics winner of the inaugural Innovation Award. The recognition was especially significant to the team because it came from members of the sleep medicine community who understand both the limitations of current diagnostics and the need for better treatment-selection tools.

The company recently closed an oversubscribed $2.4 million Seed round. Those resources are supporting its next phase, including expanding clinical evidence, working with the FDA to establish its pivotal study design, and advancing toward regulatory authorization through the De Novo pathway. In parallel, Bairitone is engaging clinicians and potential strategic partners to understand how anatomical diagnostics could fit into existing care pathways and evaluating reimbursement opportunities as part of its commercialization planning.

Longer term, Bairitone sees an opportunity for anatomical information to become part of the diagnostic process earlier in a patient’s journey.

“Anatomical information could become a routine part of sleep apnea diagnosis, giving clinicians a more complete understanding of the disease from the beginning, rather than waiting until a patient has already struggled with treatment,” Pitcher said.

Pitcher will bring Bairitone to LSI USA as the company begins building relationships with institutional investors who could participate in its next financing. Having just completed its Seed round, Bairitone is not currently raising. Instead, Pitcher sees the event as an opportunity to begin those conversations early and allow potential investors to follow the company’s progress before its next raise.

“One thing we’ve learned from our existing investors is that these relationships take time,” Pitcher said. “We’ve worked hard to build trust by communicating openly and delivering on the milestones we set out to achieve, and that’s been an important part of our fundraising experience.”

Join Us at LSI USA ‘27

Pitcher has been selected to present at LSI USA ’27, March 15th–19th, in front of hundreds of global medical technology companies. Join us in welcoming her to the event in Dana Point, CA, where she will share the latest updates on Bairitone’s technology and development.